Chongqing Precision Biotech Announces Puzolcabtagene Autoleucel Injection Selected Among Chongqing’s Top 10 Scientific and Technological Advances of 2025 2026 Chongqing Precision Biotech Co., Ltd.

Chongqing Precision Biotech Announces Puzolcabtagene Autoleucel Injection Selected Among Chongqing’s Top 10 Scientific and Technological Advances of 2025

January 15,2026

January 14, 2026 — Chongqing Academy of Science and Technology For Development announced the results of the“Top 10 Scientific and Technological Advances of Chongqing in 2025.”

Puzolcabtagene Autoleucel Injection ( PCAR-19B), a CAR-T cell therapy developed by Chongqing Precision Biotech Co., Ltd. for the treatment of pediatric and adolescent leukemia, was included in the list.

Chongqing Precision Biotech Announces Puzolcabtagene Autoleucel Injection Selected Among Chongqing’s Top 10 Scientific and Technological Advances of 2025

HOME

ABOUT US

FIELDS AND PIPELINE

PLATFORM AND TECHNOLOGY

BUSINESS AND COOPERATION

MEDIA

JOIN US

CONTACT US